Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from 4DMedical Ltd ( (AU:4DX) ) is now available.
4DMedical Limited has announced the commercial rollout of its CT:VQ™ technology at Stanford University, marking the first U.S. Academic Medical Centre to adopt the FDA-cleared technology. This move is part of a broader strategy to establish CT:VQ™ as a new standard of care in pulmonary imaging across leading U.S. institutions. Additionally, 4DMedical, in partnership with AstraZeneca, is expanding its Lung Health Screening Program in Brazil to five more hospitals, significantly increasing the program’s reach and impact. These developments are expected to accelerate clinical adoption and generate real-world evidence, positioning 4DMedical as a leader in respiratory imaging technology.
The most recent analyst rating on (AU:4DX) stock is a Hold with a A$2.00 price target. To see the full list of analyst forecasts on 4DMedical Ltd stock, see the AU:4DX Stock Forecast page.
More about 4DMedical Ltd
4DMedical Limited (ASX:4DX) is a global medical technology company that specializes in advanced imaging and artificial intelligence for respiratory care. The company offers a range of software solutions, including the FDA-cleared XV Lung Ventilation Analysis Software (XV LVAS®) and the CT:VQ™ solution, which aim to improve the detection, diagnosis, and monitoring of lung diseases. These solutions are delivered through a Software-as-a-Service (SaaS) model, integrating into existing hospital infrastructure to enhance physician productivity and patient care.
Average Trading Volume: 8,041,472
Technical Sentiment Signal: Buy
Current Market Cap: A$882.6M
See more insights into 4DX stock on TipRanks’ Stock Analysis page.